Influence of interaction between urine 11dehydrothromboxane B2 and other risk factors on disease occurrence in patients with cerebral infarction

doi:10.3969/j.issn.1006-7795.2019.05.011

Abstract

Abstract: Objective To analyze the interaction between urine 11 dehydrothromboxane B2(11-DH-TXB2) content and smoking history, drinking history, hypertension history and diabetes history in patients with cerebral infarction, and to clarify the value of 11-DH-TXB2 in the occurrence and prevention of cerebral infarction. Methods Totally 117 patients with cerebral infarction and 50 healthy controls were selected. The general data, smoking history, drinking history, hypertension and diabetes history of the patients were collected, and the content of 11-DH-TXB2 was detected. Statistical analysis was made on the difference between the two groups of 11-DH-TXB2, and the interaction model analysis between 11-DH-TXB2 and other cerebrovascular disease risk factors was carried out. Results There was no statistical difference in general data between the two groups (P>0.05). The urine 11-DH-TXB2 content, smoking history, diabetes history and hypertension history showed statistical significance between the two groups (P<0.05), while drinking history showed no statistical significance between the two groups (P>0.05).In the analysis of interaction additive model, negative interference factor (-/-) was taken as the contrast illuminance, and the OR value was set to 1, the interaction effect index (S) of the increase of 11-DH-TXB2 and smoking history was set to 1.219, the increase of 11-DH-TXB2 and hypertension history S were set to 5.578, the increase of 11-DH-TXB2 and diabetes history S were set to 4.604. Conclusion Urine 11-DH-TXB2 content is correlated with the occurrence of cerebral infarction, and has synergistic interaction with smoking history, hypertension history and diabetes history of cerebral infarction patients. 11-DH-TXB2 can be used as a risk factor for cerebral infarction prevention.

Key words: urine 11-dehydrothromboxane B2, thromboxane A2, cerebral infarction, risk factors

CLC Number:

R743.33

Wang Lingling, Chen Guixin, Wang Zhaohui, Sun Sainan, Sun Boqian, Li Wei. Influence of interaction between urine 11dehydrothromboxane B2 and other risk factors on disease occurrence in patients with cerebral infarction[J]. Journal of Capital Medical University, 2019, 40(5): 721-725.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2019.05.011

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2019/V40/I5/721

References

[1] 王陇德,刘建民,杨弋,等.我国脑卒中防治仍面临巨大挑战——《中国脑卒中防治报告2018》概要[J].中国循环杂志,2019, 34(2):105-119.
[2] 陈纪林.冠心病抗血小板治疗的进展(1)血小板在动脉粥样硬化形成和发展中的作用[J].中国循环杂志, 2004,19(1):5-6.
[3] Huang J S,Ramamurthy S K,Lin X,et al.Cell signalling through thromboxane A2 receptors[J]. Cell Signal,2004,16(5):521-533.
[4] 汪钟,胡艳华,安岩,等.动脉粥样硬化的实验研究Ⅱ中药850在防治家兔实验性动脉粥样硬化中对血栓素A2、前列腺素平衡的影响[J].中国医学科学院学报,1988,10(6):421-425.
[5] Borg C, Lim C T, Yeomans D C, et al. Purification of rat brain, rabbit aorta, and human platelet thromboxane A2/prostaglandin H2 receptors by immunoaffinity chromatography employing anti-peptide and anti-receptor antibodies[J]. J Biol Chem, 1994, 269(8):6109-6116.
[6] 王辉,董万利,方琪,等.高尿酸症合并高脂血症患者血小板活化功能的研究[J]. 中风与神经疾病杂志,2014,31(7):633-635.
[7] Wikstrom K, Kavanagh D J, Reid H M, et al. Differential regulation of RhoA-mediated signaling by the TPalpha and TPbeta isoforms of the human thromb oxane A2 receptor:independent modulation of TPalpha signaling by prostacyclin and nitric oxide[J]. Cell Signal,2008,20(8):1497-1512.
[8] 刘晓妍,杨帆,龚艳君.11-脱氢血栓素B2与阿司匹林反应性及在冠心病中的应用[J].中国接入心脏病学杂志,2018,26(3):167-171.
[9] 刘莉,叶鹏.稳定性冠状动脉疾病患者的尿11-脱氢血酸素B2与死亡率的关系[J].中华高血压杂志,2017,25(1):85.
[10] van der Plas A, Pouly S, de La Bourdonnaye G,et al.Influence of smoking and smoking cessation on levels of urinary 11-dehydro thromboxane B2[J].Toxicol Rep,2018,5:561-567.
[11] 韩国辉,李志平,姬松波.急性脑梗死患者血清血栓素B2、6-酮-前列环素F1α水平与颈动脉粥样硬化的关系[J].中国实用神经疾病杂志,2012,15(4):40-41.
[12] 陈建梅,刘姣,秦翠梅,等.莪术水煎液、配方颗粒及莪术油抗痛经作用的比较研究[J]. 中药药理与临床,2016,32(4):60-63.
[13] 陈子清,刘学源,陈玉娟,等.急性卒中患者血浆TXB2、6-Keto-PGF1α含量的变化的变化及其临床意义[J].放射免疫学杂志,2003, 16(2):66-68.
[14] 王明山,张磊,郑荣远,等.实验性颈动脉粥样硬化模型中血栓素B2和6-酮-前列腺素F1α与抗凝血酶Ⅲ和纤溶酶原活性的改变[J].中国动脉粥样硬化杂志,2001,9(2):112-114.
[15] 曲云霄,蒋知新,韩腾龙,等.血小板参数及活化标志物与2型糖尿病患者颈动脉内中膜厚度的相关性[J].实用医学杂志,2016,32(8):1250-1253.
[16] 钟广芝,胡鹏飞.百令胶囊联合环磷酰胺和醋酸泼尼松治疗肾病综合征的临床研究[J]. 现代药物与临床,2016,33(7):1028-1031.
[17] 朱玉萍,傅毅,刘桂冬,等.血栓素A2含量与脑梗死的相关性分析[J].上海交通大学学报,2009,29(9):1077-1080.
[18] 徐恩, 温海霞. 脑血管病危险因素及其干预管理[J]. 中国现代神经疾病杂志, 2015,15(1):20-26.
[19] Meschia J F, Bushnell C, Boden-Albala B, et al. Guidelines for the primary prevention of stroke:a statement for healthcare professionnals from the American heart association/American stroke association[J]. Stroke,2014, 45(12):3754-3832.
[20] 黄镪, 马青峰,宋海庆,等.血糖对急性缺血性卒中静脉溶栓治疗后结局的影响[J].首都医科大学学报,2017,38(1):53-58.
[21] 鲁明, 董荃,樊东升.缺血性卒中急性期降压治疗策略的研究进展[J].中国脑血管病杂志,2016,13(5):272-276.
[22] 刘欣, 王丽娟,刘荧,等.血压昼夜节律异常与老年轻型卒中早期进展的关系[J].中国脑血管病杂志,2017,14(7):376-379.